Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Shenzhen Hepalink Signs Two Deals with ProMetic Life Sciences

publication date: Oct 17, 2012
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Shenzhen Hepalink Pharma announced it has entered two agreements with ProMetic Life Sciences of Canada. Their total value is $21 million. Hepalink will license ProMetic’s protein technologies for an R&D project, and it will invest $10 million into ProMetic’s common stock. ProMetic said the deals will accelerate its expansion into Asia. More details....

Stock Symbols: (SHE: 002399) (TSX: PLI)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...